公开(公告)号：US20230285529A1

公开(公告)日：2023-09-14

申请号：US17778739

申请日：2020-11-23

Applicant: GRIFFITH UNIVERSITY

Inventor： Michael GOOD ,  Danielle STANISIC ,  Ashwini Kumar GIDDAM ,  Aloysious SSEMEGANDA

IPC: A61K39/015 ,  A61P33/02 ,  A61K39/018

CPC classification number: A61K39/015 ,  A61P33/02 ,  A61K39/018 ,  A61K2039/55555

Abstract: Disclosed are compositions for stimulating a protective or therapeutic immune response to an apicomplexan parasite such as those from the Plasmodium or Babesia genus. More particularly, the compositions comprise a soluble parasite extract. The extract may be free of red blood cell components and/or contained in or associated with a particle such as a liposome. The compositions and methods disclosed herein are particularly useful in the prevention and treatment of parasitic diseases.

公开(公告)号：US20190224293A1

公开(公告)日：2019-07-25

申请号：US16333675

申请日：2016-10-24

Applicant: GRIFFITH UNIVERSITY

Inventor： Michael GOOD ,  Danielle STANISIC ,  Leanne LOW

IPC: A61K39/018 ,  A61P33/06 ,  A61K31/65 ,  A61K31/7056 ,  A61K31/435 ,  A01K67/027

Abstract: Apicomplexan parasites or red blood cells infected with apicomplexan parasites are administered to an animal in combination with a delayed death agent that initially allows parasite replication but subsequently kills the apicomplexan parasites. This allows the elicitation of an immune response by the animal while preventing the parasites producing a serious infection of the animal. The apicomplexan parasites may be malaria or babesia parasites. The delayed death agent may be a tetracycline class antibiotic, a macrolide antibiotic or a lincosamide antibiotic.

公开(公告)号：US20240238398A1

公开(公告)日：2024-07-18

申请号：US18560137

申请日：2022-05-11

Applicant: GRIFFITH UNIVERSITY

Inventor： Michael GOOD ,  Hanan AL-NAZAL ,  Danielle STANISIC

IPC: A61K39/018 ,  A61K39/00 ,  A61K39/002 ,  A61K39/005 ,  A61K39/39 ,  A61P37/04

CPC classification number: A61K39/018 ,  A61K39/002 ,  A61K39/005 ,  A61K39/39 ,  A61P37/04 ,  A61K2039/515

Abstract: The present disclosure provides immunogenic compositions and methods of inducing an immune response and/or preventing, treating or ameliorating an infection, disease or condition associated with an erythrocytic organism in a first mammal, wherein the erythrocytes are from a second mammal of a species different from the first mammal.